Psychedelic Bulletin #143: Trademark Filing Reveals Potential Brand Name for MDMA; DEA “Open to Considering” Special Registration for Controlled Substances via Telemedicine; Professional Practice Guidelines for PAT; Sage’s Zuranolone Rejection

This week: will MAPS PBC’s MDMA drug product be called ‘RENSANSE’?; We look at Sage’s Zuranolone flop; DEA throws a potential lifeline to at-home ketamine providers; UK Parliamentary Office publishes note on psychedelics; and lots more…